Sangamo Therapeutics Stock Earnings Per Share
| SGMO Stock | USD 0.49 0.03 5.77% |
Sangamo Therapeutics fundamentals help investors to digest information that contributes to Sangamo Therapeutics' financial success or failures. It also enables traders to predict the movement of Sangamo Stock. The fundamental analysis module provides a way to measure Sangamo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sangamo Therapeutics stock.
Sangamo | Earnings Per Share |
Sangamo Therapeutics Company Earnings Per Share Analysis
Sangamo Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Sangamo Therapeutics Earnings Per Share | (1.48) X |
Most of Sangamo Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sangamo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Sangamo Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Sangamo Therapeutics is extremely important. It helps to project a fair market value of Sangamo Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Sangamo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sangamo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sangamo Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Sangamo Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Sangamo Therapeutics has an Earnings Per Share of -1.48 times. This is 117.68% lower than that of the Biotechnology sector and 69.1% lower than that of the Health Care industry. The earnings per share for all United States stocks is 147.44% higher than that of the company.
Sangamo Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sangamo Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sangamo Therapeutics could also be used in its relative valuation, which is a method of valuing Sangamo Therapeutics by comparing valuation metrics of similar companies.Sangamo Therapeutics is currently under evaluation in earnings per share category among related companies.
Sangamo Fundamentals
| Return On Equity | -1.36 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (1.46) % | ||||
| Operating Margin | (24.76) % | ||||
| Current Valuation | 48.36 M | ||||
| Shares Outstanding | 207.5 M | ||||
| Shares Owned By Insiders | 7.70 % | ||||
| Shares Owned By Institutions | 56.50 % | ||||
| Number Of Shares Shorted | 11.41 M | ||||
| Price To Earning | (15.31) X | ||||
| Price To Book | 1.35 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 176.23 M | ||||
| Gross Profit | (138.6 M) | ||||
| EBITDA | (92.1 M) | ||||
| Net Income | (257.83 M) | ||||
| Cash And Equivalents | 315.72 M | ||||
| Cash Per Share | 2.02 X | ||||
| Total Debt | 38.1 M | ||||
| Debt To Equity | 0.13 % | ||||
| Current Ratio | 2.86 X | ||||
| Book Value Per Share | 0.47 X | ||||
| Cash Flow From Operations | (224.84 M) | ||||
| Short Ratio | 5.05 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 405 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 108.08 M | ||||
| Total Asset | 165.32 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46.6 M | ||||
| Current Asset | 212.58 M | ||||
| Current Liabilities | 20.1 M | ||||
| Net Asset | 165.32 M |
About Sangamo Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sangamo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sangamo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sangamo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Sangamo Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Sangamo Therapeutics' short interest history, or implied volatility extrapolated from Sangamo Therapeutics options trading.
Currently Active Assets on Macroaxis
When determining whether Sangamo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sangamo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sangamo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sangamo Therapeutics Stock:Check out Sangamo Therapeutics Piotroski F Score and Sangamo Therapeutics Altman Z Score analysis. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Sangamo Stock analysis
When running Sangamo Therapeutics' price analysis, check to measure Sangamo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sangamo Therapeutics is operating at the current time. Most of Sangamo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sangamo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sangamo Therapeutics' price. Additionally, you may evaluate how the addition of Sangamo Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Commodity Directory Find actively traded commodities issued by global exchanges |
Is Sangamo Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share 1.01 | Quarterly Revenue Growth (0.93) | Return On Assets (0.18) | Return On Equity (1.36) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.